Dendritic cells loaded with heat shocked melanoma cell bodies
AssigneeBaylor Research Institute
InventorsAnna Karolina Palucka, Jacques Banchereau
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.
Claims61
A composition for inducing immunity to cancer in a patient comprising isolated and purified antigen presenting cells primed by exposure to one or more heat-shocked and killed cancer cells.
A method of inducing immunity to cancer in a patient comprising the steps of:
- heat-shocking one or more cancer cells at a temperature of at least about 42° C. for at least two hours to form heat shocked cancer cells;
- killing the heat shocked cancer cells to form heat shocked, killed cancer cells;
- incubating one or more antigen presenting cells isolated from the patient with the heat shocked, killed cancer cells for at least three hours;
- and
- administering one or more isolated, loaded antigen presenting cells to the patient.
A method of inducing immunity to cancer in a patient comprising the steps of:
- obtaining antigen presenting cells from the patient;
- incubating allogeneic cancer cells at a temperature of at least 42° C. for at least two hours to form heat shocked allogeneic cancer cells;
- killing the heat shocked allogeneic cancer cells to form heat shocked, killed allogeneic cancer cells;
- exposing the antigen presenting cells to the heat shocked, killed allogeneic cancer cells for at least three hours to form loaded antigen presenting cells;
- maturing the isolated, loaded antigen presenting cells;
- and
- administering the isolated, loaded antigen presenting cells to the patient.
A method of preparing immunogenic isolated antigen presenting cells comprising the steps of:
- isolating antigen presenting cells from a subject;
- preparing an antigen by stressing one or more cancer cells and killing the cancer cells;
- loading the antigen presenting cells with the antigen for at least three hours;
- and
- isolating and purifying the loaded antigen presenting cells.
A method of increasing the expression of tumor antigens in stressed and killed cancer cells comprising stressing the cancer cells prior to killing the cancer cells.
A method of increasing the antigenicity of tumor antigens in antigen presenting cells loaded with stressed and killed cancer cells comprising stressing the cancer cells and killing the cancer cells and exposing the antigen presenting cells to the stressed and killed cancer cells.
An antigen comprising heat shocked cancer cells and portions thereof.
A method of preparing an antigen comprising heat-treating one or more cancer cell lines and killing the cells with one or more cell death inducing agents.
An antigen comprising heat-shocked and killed cancer cells and portions thereof.
A vaccine comprising killed, allogeneic cancer cells heat-shocked at a temperature of at least 42° C. for at least two hours to form heat shocked, killed allogeneic cancer cells.
A cancer vaccine made by a method comprising the steps of:
- incubating at a temperature of at least 42° C. for at least two hours cancer cells;
- killing the heat shocked cancer cells;
- and
- loading antigen presenting cells with the heat-shocked and killed cancer cells.
A cancer vaccine for use in a patient comprising one or more at least partially mature antigen presenting cells loaded with heat shocked and killed cancer cells that are non-apoptotic.
A method of treating a cancer patient comprising:
- immunizing the patient with a cancer vaccine comprising one or more at least partially mature antigen presenting cells loaded with heat shocked and killed cancer cells that are non-apoptotic.
A method of delivering antigen to dendritic cells in vitro comprising:
- contacting dendritic cells capable of internalizing one or more antigens for antigen presentation for a time sufficient to allow the one or more antigens to be internalized for presentation to immune cells, wherein the antigen comprises heat-shocked and killed cancer cells.
Dependencies are inferred from the claim text.